Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Journal of Hepatology

Volumn 69, Issue 2, 2018, Pages 345-352

  Romano, Antonietta ^a   Angeli, Paolo ^a   Piovesan, Sara ^a   Noventa, Franco ^a   Anastassopoulos, Georgios ^a   Chemello, Liliana ^a   Cavalletto, Luisa ^a   Gambato, Martina ^a   Russo, Francesco Paolo ^a   Burra, Patrizia ^a   Vincenzi, Valter ^b   Scotton, Pier Giorgio ^c   Panese, Sandro ^d   Tempesta, Diego ^d   Bertin, Tosca ^e   Carrara, Maurizio ^f   Carlotto, Antonio ^g   Capra, Franco ^h   Carolo, Giada ^h   Scroccaro, Giovanna ⁱ   Alberti, Alfredo ^a   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b Belluno Hospital   (Italy)

^c Treviso Hospital   (Italy)

^d Angel's Hospital of Mestre   (Italy)

^e Vicenza Hospital   (Italy)

^f Bussolengo Hospital   (Italy)

^g Santorso Hospital   (Italy)

^h UNIVERSITY OF VERONA   (Italy)

ⁱ Regional Pharmaceutical Office   (Italy)

Author keywords

Advanced liver disease; Direct acting antiviral agents; Hepatitis C; Hepatocellular carcinoma; Risk factor

Indexed keywords

ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER INCIDENCE; CANCER PATIENT; DISEASE ASSOCIATION; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE; CHRONIC HEPATITIS C; COMPLICATION; DRUG EFFECT; HEPACIVIRUS; INCIDENCE; ISOLATION AND PURIFICATION; ITALY; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

EID: 85045776133     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.03.009     Document Type: Article

References (40)

1. Manns, M.P., Buti, M., Gane, E., Pawlotsky, J.M., Razavi, H., Terrault, N., et al. Hepatitis C virus infection. Nat Rev Dis Primers, 3, 2017, 17006 [Review].
2. Pawlotsky, J.M., New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 146 (2014), 1176–1192.
3. Feld, J.J., Jacobson, I.M., Hézode, C., Asselah, T., Ruane, P.J., Gruener, N., et al. For the ASTRAL-1 Investigators Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 373 (2015), 2599–2607.
4. Jacobson, I.M., Lawitz, E., Kwo, P.Y., Hézode, C., Peng, C.Y., Howe, A.Y.M., et al. Safety and efficacy of Elbasvir/Grazoprevir in patients with Hepatitis C, Virus infection and compensated cirrhosis: an Integrated Analysis. Gastroenterology 152 (2017), 1372–1382.
5. Welzel, T.M., Petersen, J., Herzer, K., Ferenci, P., Gschwantler, M., Wedemeyer, H., et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 65 (2016), 1861–1870.
6. Foster, G.R., Irving, W.L., Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., et al., On behalf of HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (2016), 1224–1231.
7. Curry, M.P., O'Leary, J.G., Bzowej, N., Muir, A.J., Korenblat, K.M., Fenkel, J.M., et al., for the ASTRAL-4 Investigators. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373 (2015), 2618–2628.
8. Charlton, M., Everson, G.T., Flamm, S.L., Kumar, P., Landis, C., Brown, R.S. Jr, et al., For the SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149 (2015), 649–659.
9. Belli, L.S., Berenguer, M., Cortesi, P.A., Strazzabosco, M., Rockenschaub, S.R., Martini, S., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. J Hepatol 65 (2016), 524–531.
10. Van der Meer, A.J., Berenguer, M., Reversion of disease manifestations after HCV eradication. J Hepatol 65 (2016), 95–108.
11. Cheung, M.C.M., Walker, A.J., Hudson, B.E., Verma, S., McLauchlan, J., Mutimer, D.J., et al., HCV Research UK. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (2016), 741–747.
12. Backus, L.I., Belperio, P.S., Shahoumian, T.A., Mole, L.A., Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology, 2017 [Epub ahead of print].
13. Delmonte RJ, Andrews B, Richards LM, Soto R, Collier S, Kuo A et al. Treatment of HCV with direct acting antivirals significantly reduces liver related hospitalizations in patients with cirrhosis. AASLD. The Liver Meeting 2017 Washington DC. October 20–24.
14. Reig, M., Mariño, Z., Perelló C., Iñarrairaegui, M., RibeiroA, Lens S., et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
15. Kozbial, K., Moser, S., Schwarzer, R., Laferl, H., Al-Zoairy, R., Stauber, R., et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment. J Hepatol 65 (2016), 856–858.
16. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Paolo Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
17. Nault, J.C., Colombo, M., Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol 65 (2016), 663–665.
18. Kobayashi, M., Suzuki, F., Fujiyama, S., Kawamura, Y., Sezaki, H., Hosaka, T., et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 89 (2016), 476–483.
19. Kozbial, K., Moser, S., Al-Zoairy, R., Schwarzer, R., Datz, C., Stauber, R., et al. Follow-up of sustained virologic responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Liver Int, 2017 [Epub ahead of print].
20. Bruno, S., Stroffolini, T., Colombo, M., Bollani, S., Benvegnù L., Mazzella, G., et al., On behalf of the Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon is associated with improved outcome in HCV-related cirrhosis: A Retrospective Study. Hepatology 48 (2007), 579–587.
21. Cardoso, A.C., Moucari, R., Figueiredo-Mendes, C., Ripault, M.P., Giuily, N., Castelnau, C., et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52 (2010), 652–657.
22. Benvegnù L., Gios, M., Boccato, S., Alberti, A., Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53 (2004), 744–749.
23. Sangiovanni, A., Prati, G.M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-Year Cohort Study of 214 Patients. Hepatology 43 (2006), 1303–1310.
24. Van der Meer, A.J., Feld, J.J., Hofer, H., Almasio, P.L., Calvaruso, V., Fernàndez-Rodrìguez, C.M., et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol, 66, 2016, 485.
25. Waziry, R., Hajarizadeh, B., Grebely, J., Amin, J., Law, M., Danta, M., et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 67 (2017), 1204–1212.
26. Kanwal, F., Kramer, J., Asch, S.M., Chayanupatkul, M., Cao, Y., El-Serag, H.B., Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 153 (2017), 996–1005.
27. Ioannou, G.N., Green, P.K., Berry, K., HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 68 (2018), 25–32.
28. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
29. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 20 (1994), 15–20.
30. http://www.webaisf.org/media/39700/documento_hcv_241017.pdf. Aghemo A, Bruno R, Ciancio A, Coco B, Petta S. AISF 2014.
31. Decreto_222_4.8.15_LineeIndirizzoDAA_EpC.pdf. Alberti A, Vincenzi V, De Boni M, Carlotto A, Pellizzer G, Fabris P, et al. Veneto Region 2015.
32. Fujiwara, N., Friedman, S.L., Goossens, N., Hoshida, Y., Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 68 (2017), 526–549.
33. Prenner, S., VanWagner, L.B., Flamm, S.L., Salem, R., Lewandowski, R.J., Kulik, L., Hepatocellular carcinoma decreases the chance of successful Hepatitis C virus therapy with direct-acting antivirals. J Hepatol 66 (2017), 1173–1181.
34. Vescovo, T., Refolo, G., Vitagliano, G., Fimia, G.M., Piacentini, M., Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect 22 (2016), 853–861.
35. Cariani, E., Pilli, M., Barili, V., Porro, E., Biasini, E., Olivani, A., et al. Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments. Oncoimmunology, 5, 2016, e1154249.
36. Spaan, M., Van Oord, G., Kreefft, K., Hou, J., Hansen, B.E., Janssen, H.L., et al. Immunological analysis during interferon-Free therapy for Chronic Hepatitis C Virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 213 (2016), 216–223.
37. Serti, E., Chepa-Lotrea, X., Kim, Y.J., Keane, M., Fryzek, N., Liang, T.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.
38. Hengst, J., Falk, C.S., Schlaphoff, V., Deterding, K., Manns, M.P., Cornberg, M., et al. Direct-acting antiviral induced hepatitis C virus clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 214 (2016), 1965–1974.
39. Meissner, E.G., Decalf, J., Casrouge, A., Masur, H., Kottilil, S., Albert, M.L., et al. Dynamic changes of post-translationally modified forms of CXCL10 and Soluble DPP4 in HCV subjects receiving Interferon-Free Therapy. PLoS One 10 (2017), 1–9.
40. Benvegnù L., Alberti, A., Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res 52 (2001), 199–207.